Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

ion with methotrexate. In preclinical studies, Rigel's R788 was shown to diminish the swelling and tissue destruction associated with RA. In addition, in a murine model of ITP, R788 was shown to increase platelet counts significantly.

Lymphoma is a large class of blood cancers that affect the lymphoid system, which is part of the immune system. In 2006, lymphoma affected an estimated 500,000 people in the United States, with 332,000 of them suffering from non-Hodgkin's varieties of the disease. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma and is generally categorized as aggressive, marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow and other organs.

A variety of treatment options exist, including chemotherapy and radiation, but the five-year survival rate for non-Hodgkin's lymphoma patients is estimated to be around 50%. Even for those who respond to treatment, recurrence of the disease is common.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates, the timing of results thereof and the potentia
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com ... report is available in its catalogue: ... (NPWT) Pipeline Technology and Market Forecasts ... ,, Negative Pressure Wound ... Forecasts to 2016 ,, Summary ...
(Date:12/17/2009)... ,Agendia, a world leader in molecular cancer ... Administration (FDA) cleared its MammaPrint breast,cancer recurrence test ... cancer recurrence test available to patients and physicians. ... four clearances for MammaPrint, covering,all aspects of this ... FDA clearance, along with our recently obtained CMS ...
(Date:12/17/2009)... LOS ANGELES, Dec. 17 Instacare Corp. ... of life-saving and life-enhancing prescription drugs and diagnostics ... ill, and a leading developer and provider of ... and products announced today that as part of ... Board has determined to add two new Directors ...
Breaking Medicine Technology:Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 2Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 3Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 4Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 5Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 6FDA Broadens Clearance for Agendia's MammaPrint(R) 2Instacare Corp. Board of Directors Sets Growth Plans for 2010 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 1SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 3Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 13147 1Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 13147 2Fecal incontinence and quality of life 52393 1
... Excellent results obtained with a newly cleared device to identify ... are associated with ... complications of coronary stenting, BURLINGTON, Mass., May 15 ... Royal Oak, Mich., have,successfully used its LipiScan(TM) Coronary Imaging System ...
... Switzerland, May 15 Ergonex Pharma today,announced that ... has,granted orphan drug designation to Terguride for the ... being evaluated for PAH,in a pivotal Phase II ... orphan drug designation to Terguride for PAH,encourages and ...
Other Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2
(Date:12/17/2009)... good time to get vaccinated, federal officials urge , ... current wave of H1N1 swine flu continues to wane, ... vaccinated in case another outbreak strikes this winter. , ... have eased, it,s an ideal time to get vaccinated, ... said during a morning press conference. , "Our message ...
(Date:12/17/2009)... pain is now available in Rockville and Gaithersburg, Maryland. This ... sometimes even fall asleep during their treatment. , ... ... Maryland can now rejoice as The Spinal Correction & Wellness Center ... discs., , ,Humans are constantly under pressure from gravitational forces which ...
(Date:12/17/2009)... Reportlinker.com announces that a ... in its catalogue: ,, http://www.reportlinker.com/p0169972/Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... the competitive environment is widely recognized ... management responsibilities, the task crucial to ... and factual competitive intelligence is vital ...
(Date:12/17/2009)... following feature is by Devon Herrick, PhD, Senior Fellow ... People often assume they have little control over how ... sickness cannot be scheduled, doctors prescribe treatments and employers ... Americans. However, there are many overlooked ways to trim ... need. ,, Cut your prescription costs: ...
(Date:12/17/2009)... China,s leading high-tech,healthcare group, Golden Meditech Company Limited ... pleased to announce today the interim results for,Financial ... Group,s two,associate companies made their debut on the ... have been strengthened, with maiden revenue and profit,contributions ... Mr. KAM Yuen, Chairman and ...
Breaking Medicine News(10 mins):Health News:Swine Flu Wanes, But Future Uncertain 2Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 2Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 3Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3
... The Alliance for Lupus Research hosts 3rd Advocacy ... March 4th,advocates for the Alliance for Lupus Research ... lupus, described their personal experiences with the,disease to ... 100,Congressional offices, representing 21 states, and asked their ...
... Quality,Improvements, * 4 p.m., Monday, March 10: ... Battery St., San Francisco, SAN FRANCISCO, March ... chain,s attempts to weaken its,employees and their union, ... is scheduled to begin., Within the next ...
... doctors twice as likely to recommend replacement surgery for men ... with knee pain are less likely than men to be ... that suggests gender bias may be a factor. , The ... with moderate knee osteoarthritis (OA) who reported the same pain ...
... 10 Tired of,frequent Botox injection visits? GFX ... Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived ... radiofrequency waves, to be,exact -- in select aesthetic ... technological advancement in facial rejuvenation that offers,long-term relaxation ...
... (WDS) is pleased to announce the 2008-2009 presidency of ... WDS luncheon during the,American Academy of Dermatology Annual Meeting ... role from this past year,s position as,WDS Vice-President and ... Lupo, MD, served as the WDS 2007-08 President., ...
... the hands of jewelers, gold can be fashioned into ... in size to nanocrystals containing a few thousand atoms, ... the key to golds chemical reactivity (or that of ... techniques work at the nanoscale. Now, researchers at the ...
Other Medicine News:Health News:Working Together for a Cure 2Health News:Working Together for a Cure 3Health News:UHW to SEIU, Nursing Home Chain: Stop Undermining Workers 2Health News:Gender Bias at Play in Treatment of Knee Osteoarthritis 2Health News:GFX: Wrinkle-Killer or Botox(R) Hit-Man? 2Health News:GFX: Wrinkle-Killer or Botox(R) Hit-Man? 3Health News:Suzanne M. Connolly, MD Named 2008-2009 President of Women's Dermatologic Society 2Health News:Measurement technique probes surface structure of gold nanocrystals 2
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
... dTC is a versatile solution designed to ... from preparation to diagnosis and therapy, ... AXIOM Artis dTC, your cath lab becomes ... that leaves you free to concentrate on ...
... AXIOM Artis FC is a ... with flexible system architecture for ... interventions. The flexible and ergonomic ... optimally adapt the system configuration ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
Medicine Products: